Spotlight on Wellness: the revolutionary world of integrative and regenerative medicine Daily Tribune (Philippines)
Follow this link:
Spotlight on Wellness: the revolutionary world of integrative and regenerative medicine - Daily Tribune (Philippines)
Blood test provides early alert to knee arthritis Cleveland Jewish News
Read more:
Blood test provides early alert to knee arthritis - Cleveland Jewish News
- Enrollment progressing well across all arms in the IMM-1-104 Phase 2a Trial, with Initial Data from Multiple Arms Expected in 2H 2024 -
See the original post here:
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
FREMONT, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2024.
More:
Cytek Biosciences Reports Second Quarter 2024 Financial Results
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fiscal first quarter ended June 30, 2024.
SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2024 and provided an update on the company’s recent developments.
View post:
FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Data Expected in September 2024 ---- Following VAX-31 Adult Phase 1/2 Study Results, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program --
Visit link:
Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the second quarter 2024.
Link:
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
Announced 3 new programs, including genetic disease programs in vascular malformations, Fabry disease, as well as precision oncology program with NRAS-specific inhibitor
Continued here:
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter of 2024 and associated Company developments.
See the rest here:
Supernus Announces Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance Reiterates Full Year 2024 Financial Guidance
Original post:
Certara Reports Second Quarter 2024 Financial Results
WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the second quarter, which ended June 30, 2024, and provided an update on recent developments in its business.
See more here:
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided business updates and reported financial results for the six-month period ending June 30, 2024.
Visit link:
Cellectis Provides Financial Results for the Second Quarter 2024
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2024.
Follow this link:
UNITY Biotechnology, Inc. Reports Second Quarter 2024 Financial Results and Business Updates
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update.
See the original post:
ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in August:
View post:
Travere Therapeutics to Present at Upcoming Investor Conferences
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
Read the rest here:
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024 Shares of BioVie common stock began trading on split-adjusted basis on August 6, 2024
Read more from the original source:
BioVie Inc. Announces Reverse Stock Split
– Agios Expects to Receive $905 Million Payment from Royalty Pharma and $200 Million Payment from Servier in Q3 2024; Payments Increase Agios’ Pro-Forma Cash Position as of June 30, 2024, to $1.7 Billion –
Here is the original post:
Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib
TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company’s name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name Change”).
Visit link:
Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.